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The immunomodulatory effect of sevoflurane in
endotoxin-injured alveolar epithelial cells
Abstract
BACKGROUND: Endotoxin-induced lung injury is a useful experimental system for the
characterization of immunopathologic mechanisms in acute lung injury. Although alveolar epithelial
cells (AEC) are directly exposed to volatile anesthetics, there is limited information about the effect of
anesthetics on these cells. In this study we investigated the effect of pretreatment with the inhaled
anesthetic sevoflurane on lipopolysaccharide (LPS)-injured AEC. METHODS: AEC were incubated
with 1.1 vol % sevoflurane for 0.5 h, followed by LPS stimulation for 5 h. Expression of monocyte
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1beta (MIP-1beta), macrophage
inflammatory protein-2 (MIP-2), cytokine-induced neutrophil chemoattractant-1 (CINC-1), and
intercellular adhesion molecule-1 (ICAM-1) was analyzed. In addition, functional tests were performed
through chemotaxis and adherence assays to underline the biological relevance of the findings.
RESULTS: Exposure of AEC to sevoflurane resulted in a 50% downregulation of MCP-1 protein in the
sevoflurane-LPS group when compared with non-sevoflurane- LPS cells (P < 0.05). MIP-1beta
concentration in LPS-stimulated cells decreased by 32% with sevoflurane (P < 0.05), MIP-2 by 29% (P
< 0.05), and CINC-1 by 20% (P < 0.05). ICAM-1 protein expression was attenuated by 36% (P < 0.05).
This inhibition caused substantial changes in the inflammatory response of neutrophils. 33% less
chemotactic activity was seen in sevoflurane-treated LPS cells (P < 0.001) as well as 47% decreased
adhesion of neutrophils to AEC (P < 0.001). CONCLUSIONS: This study shows that sevoflurane alters
the LPS-induced inflammatory response, not only with respect to the expression pattern of inflammatory
mediators, but also regarding the biological consequences with less accumulation of effector cells such
as neutrophils.
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BACKGROUND: Endotoxin-induced lung injury is a useful experimental system for the
characterization of immunopathologic mechanisms in acute lung injury. Although
alveolar epithelial cells (AEC) are directly exposed to volatile anesthetics, there is
limited information about the effect of anesthetics on these cells. In this study we
investigated the effect of pretreatment with the inhaled anesthetic sevoflurane on
lipopolysaccharide (LPS)-injured AEC.
METHODS: AECwere incubated with 1.1 vol % sevoflurane for 0.5 h, followed by LPS
stimulation for 5 h. Expression of monocyte chemoattractant protein-1 (MCP-1),
macrophage inflammatory protein-1 (MIP-1), macrophage inflammatory protein-2
(MIP-2), cytokine-induced neutrophil chemoattractant-1 (CINC-1), and intercellu-
lar adhesion molecule-1 (ICAM-1) was analyzed. In addition, functional tests were
performed through chemotaxis and adherence assays to underline the biological
relevance of the findings.
RESULTS: Exposure of AEC to sevoflurane resulted in a 50% downregulation of
MCP-1 protein in the sevoflurane-LPS group when compared with non-sevoflurane-
LPS cells (P  0.05). MIP-1 concentration in LPS-stimulated cells decreased by
32% with sevoflurane (P 0.05), MIP-2 by 29% (P 0.05), and CINC-1 by 20% (P
0.05). ICAM-1 protein expression was attenuated by 36% (P 0.05). This inhibition
caused substantial changes in the inflammatory response of neutrophils. 33% less
chemotactic activity was seen in sevoflurane-treated LPS cells (P  0.001) as well as
47% decreased adhesion of neutrophils to AEC (P  0.001).
CONCLUSIONS: This study shows that sevoflurane alters the LPS-induced inflamma-
tory response, not only with respect to the expression pattern of inflammatory
mediators, but also regarding the biological consequences with less accumulation
of effector cells such as neutrophils.
(Anesth Analg 2007;104:638–45)
Acute lung injury (ALI) and acute respiratory dis-
tress syndrome (ARDS) are characterized by a spec-
trum of increasingly severe lung injury in which
widespread damage to cells and structures of the
alveolar capillary membrane occurs within hours to
days after a predisposing insult (1). ALI/ARDS is a
major cause of acute respiratory failure with frequent
morbidity and mortality in critically ill patients (2).
The incidence of ARDS may even increase signifi-
cantly in the future because of increasing frequency of
predisposing conditions that precipitate ALI/ARDS,
such as sepsis (3). Although mortality in patients with
ALI/ARDS may have declined over the last 15 yr, it
remains high (30%–40%) (4).
Lipopolysaccharides (LPS) are bacterial endotoxins
which can lead to inflammatory reactions with patho-
logical events resembling ALI/ARDS. LPS upregulates
the expression and production of a number of chemo-
kines such as monocyte chemoattractant protein-1
(MCP-1), macrophage inflammatory protein-1 (MIP-
1), macrophage inflammatory protein-2 (MIP-2),
cytokine-induced neutrophil chemoattractant-1 (CINC-
1), as well as adhesion molecules such as intercellular
adhesion molecule-1 (ICAM-1) in vitro and in vivo (5–8).
In the respiratory compartment, alveolar epithelial cells
(AEC) are involved in the inflammatory response upon
stimulation with LPS (9–11). Through the expression
and production of these inflammatory mediators, not
only the vascular but also the airway epithelium is likely
to play an important role in the initiation and exacerba-
tion of an inflammatory response within the lungs.
In the past, volatile anesthetics have been shown to
attenuate cardiac mechanical dysfunction and limit
ultrastructural abnormalities on reperfusion after isch-
emia in the myocyte (12). Preconditioning by anesthet-
ics has become a main topic of cardiac anesthetic
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research (13). Although volatile anesthetics are deliv-
ered through the lung, there is only limited information
about their effect on different lung cells such as AEC.
Therefore, we hypothesized that the inflammatory re-
sponse of AEC to LPS-induced lung injury may also be
altered by pretreatment with volatile anesthetics.
METHODS
Alveolar Epithelial Cells (AEC)
L2 cells (CCL-149) were purchased from American
Type Culture Collection (Rockville, MD). The alveolar
epithelial L2 cell line was derived through clonal
isolation after primary plating of a cell population
from enzymatically dispersed adult rat lung. AEC
were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) (Invitrogen AG, Basel, Switzerland), which
was supplemented with 10% fetal bovine serum (FBS),
1% penicillin-streptomycin, and 1% HEPES buffer.
Using 35 10 mm plates (Corning, Corning, NY) AEC
were grown until confluence.
Sevoflurane Exposure and Stimulation with LPS
Medium of confluent monolayers of AEC was
changed to DMEM/1% FBS and placed in a pre-
heated (37°C) 3.5 L air-tight chamber (Oxoid, Basel,
Switzerland).
In a first approach AEC were exposed to 0.5, 1.1,
2.2, 3.3 vol % sevoflurane (Sevorane, Abbott, Swit-
zerland) for 0.5, 2, 4, and 12 h. A mixture of 5% CO2
and 95% air was directed through a Sevotec 5 Vapor-
izer (Abbott, Switzerland), placed at the entrance of
the chamber (for controls only CO2/air mixture).
These sevoflurane concentrations were chosen accord-
ing to the one minimum alveolar concentration (MAC)
value of 2.2 vol % for this anesthetic in young humans
(0.5, 1.1, 2.2, and 3.3 vol % representing 0.25, 0.5, 1, and
1.5 MAC). A 5330 Agent Monitor (Datex-Ohmeda,
Duisburg, Germany) determined the concentration of
the volatile anesthetic exiting the chamber. The cham-
ber was sealed upon reaching the desired concentra-
tion and incubated at 37°C. The chamber atmosphere
was kept saturated continuously with H2O. After
exposure of AEC to the volatile anesthetic, cells were
washed twice with warm phosphate-buffered saline
(PBS) and incubated with LPS from Escherichia coli
serotype 055:B5 (LPS; 20 g/mL; Sigma-Aldrich,
Buchs, Switzerland) (or PBS as a control) for 1, 3, 5, 7,
12, 18, 24 h in a normal incubator with 5% CO2 and
95% air at 37°C.
Concentrations of the volatile anesthetic were con-
trolled. There was no variation between the concen-
tration measured before sealing the chamber and the
end of the experiment.
Viability of cells was determined by the trypan blue
dye exclusion assay. In addition, results were con-
firmed with a cytotoxicity assay (determination of
lactate dehydrogenase) (Promega, Madison, WI).
RNA Extraction and Reverse Transcriptase-Polymerase
Chain Reaction (RT-PCR) Analysis
Total cellular RNA was isolated from treated AEC.
Following manufacturer’s instructions, the cells were
lysed by adding monophasic solution of phenol and
guanidine isothiocyanate (TRIzol Reagent, Invitro-
gen AG, Basel, Switzerland). RNA was precipitated
with chloroform and isopropanol, washed with 75%
ethanol, and finally dissolved in RNAase-free water.
Total amounts of cellular RNA were determined by
absorbance at 260 nm.
Random hexanucleotide primers and murine leu-
kemia virus reverse transcriptase were used for cDNA
synthesis. Reverse transcription was performed with
0.8 g RNA at 20°C for 5 min, 42°C for 30 min and
99°C for 5 min. Specific primers located on separate
exons were designed to asses gene expression of
MCP-1, MIP-2, CINC-1, and ICAM-1 in AEC (summa-
rized in Appendix 1 available at www.anesthesia-
analgesia.org).
RT-PCR reaction products were resolved on 1.5%
agarose gels (Invitrogen AG) and stained with ethidium
bromide. Polymerase chain reaction was also performed
with 18S primers to ensure equal loading.
Enzyme-Linked Immunosorbent Assay for MCP-1, MIP-2,
and CINC-1
To measure MCP-1, MIP-2, and CINC-1 protein
production in the supernatant of AEC, ELISA was per-
formed according to the manufacturer’s recommenda-
tions, using OptEIA™ rat MCP-1 ELISA (Pharmingen,
San Diego) and rat MIP-2 and CINC-1 ELISA (R&D
Systems, Abingdon, UK), respectively. Optical density
was determined at 492 nm and the results were given in
pg/mL.
Western Blot Analysis for MIP-1
Characterization of proteins was performed using a
SDS-polyacrylamide gel. Twenty-five microliters of
collected supernatants of AEC were electrophoresed
and after separation, proteins were transblotted to a
nitrocellulose membrane for 2 h at 200 mA. After
washing with PBS, the membrane was blocked with
PBS/4% low fat milk/0.1% Tween 20 for 1 h at room
temperature, followed by overnight incubation with a
polyclonal rabbit anti-rat MIP-1 antibody (Biosource
Int. Camarilla, CA) in blocking buffer at 4°C. All
washing steps were performed three times with
PBS/0.1% Tween 20. A secondary horseradish
peroxidase-labeled anti-rabbit IgG (1:5000) (Sigma-
Aldrich) in blocking buffer was added for 1 h at room
temperature. Signals were detected by enhanced chemi-
luminescence.
Cell-Based ELISA for ICAM-1
AEC were added to 96-well plates and grown to
confluence at 37°C in 5% CO2. Cells were exposed to
sevoflurane and stimulated with LPS, as described
earlier. After washing once with PBS, cells were fixed
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with PBS/3% paraformaldehyde for 15 min at room
temperature (14). After each incubation step, the cells
were washed three times with PBS. Incubation over-
night at 4°C with the primary antibody was per-
formed with monoclonal mouse anti-rat ICAM-1
antibody (1A29; Serotec, Oxford, UK) diluted in
PBS/5% FBS to a concentration of 0.5 g/mL. After a
washing step, the cells were incubated with the sec-
ondary goat anti-mouse IgG, conjugated with horse-
radish peroxidase (1:2500 in PBS/5% FBS; 1 h at room
temperature). The washing procedure was repeated
and 200 L of o-phenylenediamine dihydrochloride
solution (Sigma-Aldrich) was added to each well and
plates were incubated for min at room temperature in
the dark. Finally, the reaction was stopped with 3 M
H2SO4 and the optical density was determined at 492
nm. The optical density values were interpreted as up
or downregulation of ICAM-1 when compared with
control groups.
Preparation of Neutrophils (Polymorphonuclear
Cells, PMN)
Human neutrophils were isolated by gradient cen-
trifugation over Ficoll-Paque (Amersham Pharmacia
Biotech, Dubendorf, Switzerland) followed by 1%
dextran sedimentation for 1 h to separate neutrophils
from erythrocytes (9). After centrifugation of the su-
pernatant, the contaminating erythrocytes were lysed
with distilled water followed by the addition of 2.7%
NaCl to stop hypotonic lysis. The remaining neutro-
phils were resuspended in DMEM/1% FBS. Neutro-
phils were labeled at a total concentration of 5  106
PMN/mL and a concentration of 5 M of the fluores-
cent indicator calcein acetoxymethyl ester (Calcein
AM, Calbiochem Biochemicals, Juro supply, Switzer-
land) for 30 min at 37°C. PMN were subsequently
washed twice with PBS and resuspended in DMEM/1%
FBS at the desired concentration.
Chemotaxis Assay
1  105 calcein-AM-labeled neutrophils were given
into the upper chamber of MultiScreen-MIC filter plates
(Millipore, France). Receiver plates were loadedwith 150
L of supernatant of previously treated cells as de-
scribed earlier (5 h LPS stimulation). The chemotactic
substance N-formylmethionyl-leucyl-phenylalanine 0.1
M, (Sigma-Aldrich) was taken as positive control,
while DMEM/1% FBS was used to determine basal
migration. After 2 h incubation at 37°C, the filter plate
was taken out and migrated cells were lysed with 1.0%
Triton-X (Sigma-Aldrich). Fluorescence was measured
by using an excitation filter at 485 nm and an emission
filter at 535 nm. The ratio between migration to super-
natant of stimulated AEC and basal migration was used
as indication of PMN chemotaxis.
Assay of Neutrophil Adherence to AEC
AEC were added to 6-well plates and grown to
confluence at 37°C in 5% CO2. Cells were exposed to
sevoflurane and stimulated with LPS as described
earlier (5 h LPS stimulation). AEC were washed with
DMEM after stimulation and 5  105 calcein-AM-
labeled PMN were added to each well for 30 min at
37°C. Nonadherent PMN were removed by carefully
washing the cells twice with DMEM. DMEM 100 L
was added to each well before fluorescent measure-
ment and then fluorescence was measured using an
excitation filter at 485 nm and an emission filter at 535
nm. The amount of adherent PMN was calculated by
using a standard row.
For ICAM-1-blocking studies on AEC after stimu-
lation, cells were preincubated with anti-ICAM-1
(1A29) or control antibody (MOPC-21, Serotec, Oxford,
UK) at a concentration of 10 g/mL at 37°C for 20 min
(14). At the same time, neutrophils were preincubated
with anti-FcRIII (CD16) and anti-FcRII (CD32) anti-
bodies (Becton Dickinson, Switzerland) at a concentra-
tion of 10 g/mL for each antibody in DMEM at 37°C
for 15 min. AEC and neutrophils were washed once
with DMEM and incubated together as described
earlier.
Statistical Analysis
In all experiments, statistical significance was evalu-
ated using the paired Student’s t-test at a 5% level. Each
experimental setupwas performed five times. Values are
expressed as mean  sem. To calculate percent protec-
tion, all values after LPS stimulation were adjusted by
subtraction of negative control values. Non-sevoflurane-
LPS groups were then compared with sevoflurane-LPS
groups.
RESULTS
All results presented from RT-PCR were analyzed
by densitometry and presented in a quantitative man-
ner with regard to the fact that RT-PCR is only a
semiquantitative method. Original blots are available
at www.anesthesia-analgesia.org.
Evaluation of Optimal Pretreatment of AEC
with Sevoflurane
In a first approach, different concentrations of the
volatile anesthetic were evaluated to determine the
optimal effect of pretreatment of AEC with sevoflu-
rane. AEC were exposed to 0.5, 1.1, 2.2, and 3.3 vol %
sevoflurane for 0.5 h, followed by LPS stimulation for
3 h. To evaluate the effect of time regarding pretreat-
ment of AEC with 1.1 vol % sevoflurane, cells were
exposed to the anesthetic for various time periods (0.5,
2, 4, and 12 h), followed by stimulation with LPS for
3 h (summarized in Appendix 2 available at www.
anesthesia-analgesia.org).
For all these experiments, decreased expression of
inflammatory mediators due to increased rate of cell
necrosis could be excluded with trypan blue staining
and lactate dehydrogenase assays.
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These preliminary experiments showed that a
sevoflurane exposure time of 0.5 h with a concentra-
tion of 1.1 vol % induced the most pronounced
suppression regarding MCP-1 expression. Therefore,
the following experiments were performed under
these conditions.
Effect of Various LPS Exposure Times on MCP-1 Expression
in AEC After Sevoflurane Pretreatment
To evaluate the effect of sevoflurane at various time
points after LPS stimulation, cells were exposed to
sevoflurane for 0.5 h with a concentration of 1.1 vol %,
followed by a stimulation with LPS 20 g/mL or PBS
as a control. AEC were stimulated with LPS for 1, 3, 5,
7, 12, 18, and 24 h. The most pronounced increase of
mRNA for MCP-1 was seen after 7–12 h of LPS
exposure with more than 200% enhanced expression
(P  0.05) versus the control group. After sevoflurane
pretreatment, a statistically significant downregula-
tion of mRNA for MCP-1 was found at 1, 3, and 5 h
LPS exposure (63%, 139%, 41%, P  0.05) and after 12
and 24 h (both 37%, P  0.05). No difference was seen
after 7 and 18 h (Fig. 1A). This downregulation ofMCP-1
mRNA showed a biphasic pattern. All densitometries
were compared with 18S (figures not shown).
MCP-1 protein concentration in supernatants of
non-sevoflurane-LPS exposed AEC was upregulated
from 0.4  0.0 ng/mL in the non-sevoflurane-PBS
group to 147.8  6.5 ng/mL at 24 h in the non-
sevoflurane-LPS group (P  0.001). Exposing cells
to sevoflurane before LPS-stimulation showed the
following downregulation when compared with non-
sevoflurane-LPS cells: at 1 h, MCP-1 was downregu-
lated by 9% (P  0.05), at 3 h by 16% (P  0.05), at 5 h
by 50% (P  0.05), at 12 h by 10% (P  0.01), and at
24 h by 21% (P  0.05). There was no statistically
significant difference after 7 and 18 h of LPS stimula-
tion (Fig. 1B).
Effect of Various LPS Exposure Times on MIP-1,
MIP-2, CINC-1, and ICAM-1 Expression in AEC After
Sevoflurane Pretreatment
Although several primers had been tested for
mRNA for MIP-1, results were not conclusive. There-
fore, we focused on the protein only, as this also
represents the major component for biological activity.
MIP-1 protein showed an increase of more than 300%
in non-sevoflurane-LPS cells when compared with non-
sevoflurane-PBS cells (P 0.005). In the sevoflurane-LPS
group, mRNA for MIP-1 was decreased by 24% at 5 h
compared to the non-sevoflurane-LPS group (P  0.05)
(Fig. 2).
Upon LPS stimulation, MIP-2 mRNA increased
rapidly in non-sevoflurane-exposed cells and reached
a maximal expression after 1 h of LPS stimulation with
an increase of 52% (P  0.005). The addition of 1.1 vol
% sevoflurane for 0.5 h was associated with a signifi-
cant decrease of MIP-2 mRNA with 35% after 3 h, 49%
after 5 h, and 131% after 7 h (all P  0.05) (Fig. 3A).
Only small amounts of MIP-2 protein were measured
in the supernatant. After LPS stimulation, MIP-2 in-
creased by 29% after 5 h (P  0.05) and by 75% after
7 h (P  0.01). MIP-2 was decreased by 22% after 7 h,
exposing cells to 1.1 vol % sevoflurane before endo-
toxin stimulation (P  0.05) (Fig. 3B).
CINC-1 mRNAwas determined after 1, 3, 5, and 7 h
of LPS stimulation time after a prior administration of
1.1 vol % sevoflurane or control gas for 0.5 h. LPS
stimulation led to a maximum increase of CINC-1
mRNA of 400% after 5 h (P  0.001). Treatment with
Figure 1.A: Evaluation of sevoflurane administration regard-
ing mRNA expression for monocyte chemoattractant
protein-1 (MCP-1). Confluent layers of alveolar epithelial
cells (AEC) were pretreated with 1.1 vol % sevoflurane for
0.5 h (or with a control gas), followed by stimulation with
lipopolysaccharide (LPS, 20 g/mL) or phosphate-buffered
saline (PBS) as a control for 1, 3, 5, 7, 12, 18, and 24 h. Total
cellular mRNA was extracted and MCP-1 mRNA was de-
termined by and reverse transcriptase-polymerase chain
reaction (RT-PCR). Densitometry was performed and values
adapted to 18S. One value for non-Sevo-PBS was defined as
1 and all other values were adapted. Values are mean sem
from five experiments. #P 0.05 between non-Sevo-PBS and
non-Sevo-LPS, *P  0.05 between non-Sevo-LPS and Sevo-
LPS. B: Evaluation of sevoflurane administration regarding
protein expression of monocyte chemoattractant protein-1
(MCP-1). Confluent layers of AEC were pretreated with 1.1
vol % sevoflurane for 0.5 h (or with a control gas), followed
by stimulation with lipopolysaccharide (LPS, 20 g/mL) or
phosphate-buffered saline (PBS) as a control for 1, 3, 5, 7, 12,
18, and 24 h. MCP-1 ELISA was performed with superna-
tants. Values are mean  sem from five experiments. #P 
0.05 between non-Sevo-PBS and non-Sevo-LPS, *P  0.05
between non-Sevo-LPS and Sevo-LPS.
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1.1 vol % sevoflurane was associated with a decrease
of 46% at 1 h when compared with the non-
sevoflurane-LPS group (P 0.005) (Fig. 4A). After LPS
stimulation, CINC-1 protein concentration increased
from a baseline expression of 0.3  0.0 ng/mL up to
2.9  0.1 ng/mL (P  0.005) at 3 h and 13.8  0.4
ng/mL at 7 h (P  0.001). Exposing AEC to sevoflu-
rane before LPS stimulation decreased the CINC-1
concentration by 33% at 3 h, P  0.05) and 20% at 5 h
(P  0.05) (Fig. 4B).
For ICAM-1 mRNA, a modest upregulation in non-
sevoflurane-LPS stimulated cells was measured when
compared with the non-sevoflurane-PBS group: 28%
after 3 h, 50% at 5 h, and 32% at 7 h (P  0.05). No
statistically significant decrease of ICAM-1 mRNA was
detected in the sevoflurane-LPS group (Appendix for
Fig. 5 available at www.anesthesia-analgesia.org). This
might have been due to a lack of sensitivity of the PCR
method. A cell-based ELISA was performed to deter-
mine ICAM-1 protein on the surface of AEC, focusing on
pretreatment with sevoflurane or control gas, followed
by 5 h of LPS stimulation. There was a small but signifi-
cant upregulation of ICAM-1 protein in non-sevoflurane
LPS cells when compared with the non-sevoflurane PBS
group (27% increase, P  0.001). Thirty-six percent less
ICAM-1 protein was found in the sevoflurane pre-
treated LPS group when compared with non-
sevoflurane-LPS cells (P  0.05) (Fig. 5).
Chemotaxis Assay
Chemotaxis assays were performed to assess the
biological function of the released chemokines. The
results showed a 68% (P  0.001) increase of migrated
PMN to the supernatant of LPS stimulated cells (5 h
LPS stimulation) when compared with the superna-
tants of control cells. Chemotaxis of neutrophils to the
supernatant of LPS-stimulated cells, previously ex-
posed to 1.1 vol % sevoflurane for 0.5 h, decreased by
33% (P  0.05) (Fig. 6A).
Adherence Assay
To evaluate the biological implication of ICAM-1
expression on AEC, adherence assays with neutro-
phils were performed. Compared to non-sevoflurane
Figure 2. Evaluation of sevoflurane administration regarding
protein expression of macrophage inflammatory protein-1
(MIP-1). Confluent layers of alveolar epithelial cells (AEC)
were pretreated with 1.1 vol % sevoflurane for 0.5 h (or with
a control gas), followed by stimulation with lipopolysaccha-
ride (LPS, 20 g/mL) or phosphate-buffered saline (PBS) as
a control for 5 h. MIP-1 was examined using Western blot
analysis. Densitometry was performed. One value for non-
Sevo-PBS was defined as 1 and all other values were
adapted. Values are mean  sem from five different assays
(no SEM for non-Sevo-PBS and sevo-PBS values). #P  0.005
between non-Sevo-PBS and non-Sevo-LPS, *P  0.05 be-
tween non-Sevo-LPS and Sevo-LPS.
Figure 3.A: Evaluation of sevoflurane administration regard-
ing mRNA expression for macrophage inflammatory
protein-2 (MIP-2). Confluent layers of alveolar epithelial
cells (AEC) were pretreated with 1.1 vol % sevoflurane for
0.5 h (or with a control gas), followed by stimulation with
lipopolysaccharide (LPS, 20 g/mL) or phosphate-buffered
saline (PBS) as a control for 1, 3, 5, and 7 h. Total cellular
mRNA was extracted and MIP-2 mRNA was determined by
reverse transcriptase-polymerase chain reaction (RT-PCR).
Densitometry was performed and values adapted to 18S.
One value for non-Sevo-PBS was defined as 1 and all other
values were adapted. Values are mean  sem from five
experiments. #P  0.05 between non-Sevo-PBS and non-
Sevo-LPS, *P  0.05 between non-Sevo-LPS and Sevo-LPS.
B: Evaluation of sevoflurane administration regarding pro-
tein expression of monocyte chemoattractant protein-1
(MIP-2). Confluent layers of AEC were pretreated with 1.1
vol % sevoflurane for 0.5 h (or with a control gas), followed
by stimulation with lipopolysaccharide (LPS, 20 g/mL) or
PBS as a control for 1, 3, 5, and 7 h. MIP-2 ELISA was
performed with supernatants. Values are mean  sem from
five experiments. #P  0.05 between non-Sevo-PBS and non-
Sevo-LPS, *P  0.05 between non-Sevo-LPS and Sevo-LPS.
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PBS cells, adherence of neutrophils to non-sevoflurane
LPS AEC increased by 78% (P  0.001). Neutrophil
adherence to sevoflurane-LPS cells decreased by 47%
(P  0.001). In the presence of blocking antibodies to
ICAM-1, neutrophil adherence to non-sevoflurane-
LPS cells was decreased by 38% (P  0.001), and in
sevoflurane-LPS cells by 14% (P  0.05) (Fig. 6B).
DISCUSSION
LPS in the lung has been shown to trigger the
release of a number of mediators, such as chemokines,
cytokines, and cell adhesion molecules. These events
combine to aid in the migration and activation of
effector cells, such as alveolar macrophages and PMN
cells (15). AEC are a potent source of inflammatory
mediators within the respiratory compartment of the
lung upon endotoxin stimulation (16). Sevoflurane, a
newer volatile anesthetic, has antiinflammatory prop-
erties in the heart, as previously demonstrated (13).
Because AEC are directly exposed to volatile anesthet-
ics, this study investigated potential inflammation-
modifying effects of sevoflurane in a model of ALI. The
main results of our study showed downregulation of
chemokines and adhesion molecules, released by AEC
upon LPS stimulation after pretreatment with sevoflu-
rane, with the concomitant biological consequences.
Pharmacological preconditioning is a powerful cell-
protective mechanism conferring relative resistance
against myocellular death resulting from ischemia-
reperfusion injury (13). Some volatile anesthetics also
protect against ischemia-reperfusion injury in kidneys
by attenuating inflammation (17). A study in rat
alveolar Type II cells showed that exposure to volatile
anesthetics altered secretion of inflammatory media-
tors upon interleukin-1 stimulation (18). Halothane,
isoflurane, and enflurane decreased production of
interleukin-6, MIP-2, and MCP-1 protein concentra-
tions in a dose- and time-dependent manner. Other in
Figure 4.A: Evaluation of sevoflurane administration regard-
ing mRNA expression for cytokine-induced neutrophil
chemoattractant-1 (CINC-1). Confluent layers of alveolar
epithelial cells (AEC) were pretreated with 1.1 vol % sevoflu-
rane for 0.5 h (or with a control gas), followed by stimulation
with lipopolysaccharide (LPS, 20 g/mL) or phosphate-
buffered saline (PBS) as a control for 1, 3, 5, and 7 h. Total
cellular mRNA was extracted and CINC-1 mRNA was
determined by reverse transcriptase-polymerase chain reac-
tion (RT-PCR). Densitometry was performed and values
adapted to 18S. One value for non-Sevo-PBS was defined as
1 and all other values were adapted. Values are mean sem
from five experiments. #P  0.05 between non-Sevo-PBS
and non-Sevo-LPS, *P  0.005 between non-Sevo-LPS and
Sevo-LPS. B: Evaluation of sevoflurane administration
regarding protein expression of cytokine-induced neutro-
phil chemoattractant-1 (CINC-1). Confluent layers of AEC
were pretreated with 1.1 vol % sevoflurane for 0.5 h (or with
a control gas), followed by stimulation with lipopolysaccha-
ride (LPS, 20 g/mL) or phosphate-buffered saline (PBS) as
a control for 1, 3, 5, and 7 h. CINC-1 ELISA was performed
with supernatants. Values are mean  sem from five experi-
ments. #P  0.05 between non-Sevo-PBS and non-Sevo-LPS,
*P  0.05 between non-Sevo-LPS and Sevo-LPS.
Figure 5. Evaluation of sevoflurane administration regarding
protein expression of intercellular adhesion molecule-1
(ICAM-1). Confluent layers of alveolar epithelial cells (AEC)
were pretreated with 1.1 vol % sevoflurane for 0.5 h (or with
a control gas), followed by stimulation with lipopolysaccha-
ride (LPS, 20 g/mL) or phosphate-buffered saline (PBS) as
a control for 5 h. Monolayers were fixed, and ICAM-1 was
determined by direct cellular ELISA. Values are mean sem
from five experiments. #P  0.001 between non-Sevo-PBS
and non-Sevo-LPS, *P  0.05 between non-Sevo-LPS and
Sevo-LPS.
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vitro studies demonstrated that halothane altered sur-
factant phospholipids and apoprotein biosynthesis by
rat Type II AEC and decreased Na, K-ATPase-, and
sodium channel activities (19,20). Our results with a
sevoflurane-induced downregulation of inflammatory
mediators are in accordance with these previous find-
ings, although the experimental setup was different.
They suggest that this sevoflurane-induced inhibiting
effect in LPS-induced lung injury may be dose-
dependent within a range of 1.1–2.2 vol% sevoflurane,
a concentration which is also clinically applicable.
Comparing our findings with results from Giraud et
al. (18), testing halothane, or with Kehl et al. (21),
working with isoflurane, it seems that the threshold
concentration required for a certain effect may be
specific for a given volatile anesthetic.
In contrast to these findings, several studies have
revealed that the use of volatile anesthetics modulate
expression of inflammatory mediators into the oppo-
site direction. Kotani et al. (22) found that the exposure
of rat alveolar macrophages to volatile anesthetics
augmented mRNA expression of proinflammatory
cytokines. Sevoflurane also increased pulmonary NO3
and NO2 production in anesthetized pigs (23). A
possible explanation of these contradictory results
might be the differences in experimental setups, the
use of several volatile anesthetics, the concentration of
the volatile anesthetic, and the time of exposure.
In our model, important PMN chemoattractants,
such as MIP-2 and CINC-1, were determined. MCP-1
was chosen because it is not only as a monocyte but
also as a neutrophil chemoattractant. MCP-1 has been
shown to play a pivotal role in PMN recruitment in
various experimental systems: MCP-1 was demon-
strated to be important for neutrophil recruitment in
hyperoxia-exposed rat (24). Also, studies in a model of
LPS-induced lung injury showed that MCP-1 is in-
volved in accumulation of neutrophils (25).
The biological aspect of this study is noteworthy: we
could show that sevoflurane suppresses the expression
of inflammatory mediators with subsequent important
biological relevance. Because chemokines are implicated
in effector cell recruitment toward target tissues, the
effect of sevoflurane on LPS-stimulated AEC was inves-
tigated performing chemotaxis assays. LPS stimulation
of AEC induced enhanced chemotaxis. Notably, with
sevoflurane pretreatment, chemotactic potency was de-
creased. These results suggest that sevoflurane reduces
AEC-induced accumulation of neutrophils in LPS injury.
Increased adhesiveness between pneumocytes and
neutrophils in the setting of an inflammatory response
would be expected to lead to intensified injury of the
alveolar cell-lining barrier (11,26). Results of the ad-
herence assays demonstrated a functional role for
ICAM-1 in the adhesion of neutrophils to LPS-
stimulated AEC. With sevoflurane, decreased adhe-
sion of these effector cells to AEC could be shown,
assuming that epithelial cell killing might also be
impaired. This would imply a diminished grade of
injury.
In summary, we demonstrated that sevoflurane
pretreatment decreased the production of inflamma-
tory mediators in AEC in LPS-induced injury. The
advantage of the respiratory compartment is the abun-
dance of available tissue for analysis of inflammatory
reactions at the interface of the external and internal
Figure 6. A: Determination of chemotactic activity in super-
natants of alveolar epithelial cells (AEC). Calcein-AM-
labeled neutrophils were given into MultiScreen-MIC filter
plates, while receiver plates were loaded with 150 L of
supernatant of previously sevoflurane/non-sevoflurane pre-
treated phosphate-buffered saline (PBS)- or lipopolysaccaride
(LPS)-exposed cells. Dulbecco’s modified Eagle’s medium
(DMEM) 1% fetal bovine serum (FBS) was taken to deter-
mine basal migration. After 2 h of incubation, fluorescence
was measured by using an excitation filter at 485 nm and an
emission filter at 535 nm. Ratio between migration to
supernatant of stimulated AEC and basal migration was
used as indication of PMN chemotaxis. Values are mean 
sem from five experiments. *P 0.05 between non-Sevo-PBS
and Sevo-PBS as well as between non-Sevo-LPS and Sevo-
LPS. B: Neutrophil adhesion to AEC cell monolayers. Cells
were exposed to sevoflurane or control gas and stimulated
with LPS for 5 h. Cells were preincubated with anti-ICAM-1
(1A29) or control antibody (MOPC-21). At the same time,
neutrophils were preincubated with anti-FcRIII (CD16) and
anti-FcRII (CD32) antibodies  calcein-AM-labeled PMN
were added to each well for 30 min. Nonadherent PMN
were removed by carefully washing the cells twice with
DMEM. Fluorescence was measured by using an excitation
filter at 485nm and an emission filter at 535nm. The amount
of adherent PMN was calculated by using a standard row.
Values are mean  sem from five experiments. #P  0.05
between non-Sevo-PBS and non-Sevo-LPS, *P  0.05 be-
tween non-Sevo-LPS and Sevo-LPS.
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environments. The lung offers easy accessibility for
therapeutic interventions. Attenuation of injury by
application of sevoflurane in the ALI could be a
promising option for clinical application. However,
exact information about cellular signaling upon inter-
action of sevoflurane with the target cell has to be
evaluated.
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